Patents by Inventor Lance E. Steward

Lance E. Steward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273985
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • POST-TRANSLATIONAL MODIFICATION AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273986
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Botulinum neurotoxin serotype B activatable Botulinum neurotoxin serotype Bs
    Patent number: 7815917
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: October 19, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Melvin S. Oka
  • Multivalent clostridial toxins
    Patent number: 7811584
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: October 12, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Activatable clostridial toxins
    Patent number: 7749514
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: July 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • Cell compositions useful for cell-based FRET assays for clostridial toxins
    Patent number: 7749759
    Abstract: The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: July 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
  • Chimera Botulinum Toxin Type E
    Publication number: 20100160609
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: June 24, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Activatable clostridial toxins
    Patent number: 7740868
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: June 22, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100151494
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: June 17, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Leucine-based motif and clostridial neurotoxins
    Patent number: 7723480
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: May 25, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • Fret protease assays for botulinum serotype A/E toxins
    Patent number: 7718766
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: May 18, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • CHIMERA BOTULINUM TOXIN TYPE E
    Publication number: 20100121042
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: May 13, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Substrates useful for FRET protease assays for botulinum serotype A/E toxins
    Patent number: 7709608
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: May 4, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Leucine-based motif and Clostridial neurotoxins
    Patent number: 7705125
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: April 27, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • Leucine-based motif and clostridial neurotoxins
    Patent number: 7705124
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: April 27, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • Leucine-based motif and clostridial neurotoxins
    Patent number: 7691974
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • Chimera botulinum toxin type E
    Patent number: 7691983
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100081157
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100081158
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100075358
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki